Adam Pacławski

Dr. Adam Pacławski

Jagiellonian University Medical Collage
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in International Journal of Nanomedicine
Verified
Journal Article
Open access
Aleksander MendykAleksander Mendyk
Aleksander Mendyk
Jakub SzlękJakub Szlęk
Jakub Szlęk
RJRenata Jachowicz
Renata Jachowicz
RLRaymond Lau
Raymond Lau
Adam PacławskiAdam Pacławski
Adam Pacławski
Peer reviewed article authored by (Szlęk J, Pacławski A, Lau R, Jachowicz R, Mendyk A). Read article or submit your manuscript for publishing.

18 April 2023 in Molecular Pharmaceutics
Verified
Journal Article
Open access
NŁNatalia Łapińska
Natalia Łapińska
Jakub SzlękJakub Szlęk
Jakub Szlęk
Adam PacławskiAdam Pacławski
Adam Pacławski
KKKlaudia Klimończyk
Klaudia Klimończyk
MPMatteo Puccetti
Matteo Puccetti
Aleksander MendykAleksander Mendyk
Aleksander Mendyk
Oral medicines represent the largest pharmaceutical market area. To achieve a therapeutic effect, a drug must penetrate the intestinal walls, the main absorption site for orally delivered active pharmaceutical ingredients (APIs). Indeed, predicting drug absorption can facilitate candidate screening and reduce time to market. Algorithms are available with good prediction accuracy that however focus only on solubility. In this work, we focused on drug permeability looking at human intestinal absorption as a marker for intestinal bioavailability. Being of considerable therapeutic relevance, APIs with serotonergic activity were selected as a dataset. Due to process complexity, experimental data scarcity, and variability, we turned toward an artificial intelligence (AI)-based system, which is a hierarchical combination of classification and regression models. This combination of seemingly two models into a single system widens the space of molecules classified as highly permeable with high accuracy. The specialized and optimized system enables in silico and structure-based prediction with a high degree of certainty. Predictions in external validation allowed correct selection of the 38% of highly permeable molecules without any false positives. The proposed system based on AI represents a promising tool useful for oral drug screening at an early stage of drug discovery and development. Datasets and the obtained models are available on the GitHub platform (https://github.com/nczub/HIA_5-HT).

1 January 2013 in Dissolution Technologies
Verified
Journal Article
Closed access
Aleksander MendykAleksander Mendyk
Aleksander Mendyk
Adam PacławskiAdam Pacławski
Adam Pacławski
JSJakub Szlek
Jakub Szlek
RJRenata Jachowicz
Renata Jachowicz

13 April 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Jakub SzlękJakub Szlęk
Jakub Szlęk
MKMohammad Hassan Khalid
Mohammad Hassan Khalid
Adam PacławskiAdam Pacławski
Adam Pacławski
NŁNatalia Łapińska
Natalia Łapińska
Aleksander MendykAleksander Mendyk
Aleksander Mendyk
Tablets are the most common dosage form of pharmaceutical products. While tablets represent the majority of marketed pharmaceutical products, there remain a significant number of patients who find it difficult to swallow conventional tablets. Such difficulties lead to reduced patient compliance. Orally disintegrating tablets (ODT), sometimes called oral dispersible tablets, are the dosage form of choice for patients with swallowing difficulties. ODTs are defined as a solid dosage form for rapid disintegration prior to swallowing. The disintegration time, therefore, is one of the most important and optimizable critical quality attributes (CQAs) for ODTs. Current strategies to optimize ODT disintegration times are based on a conventional trial-and-error method whereby a small number of samples are used as proxies for the compliance of whole batches. We present an alternative machine learning approach to optimize the disintegration time based on a wide variety of machine learning (ML) models through the H2O AutoML platform. ML models are presented with inputs from a database originally presented by Han et al., which was enhanced and curated to include chemical descriptors representing active pharmaceutical ingredient (API) characteristics. A deep learning model with a 10-fold cross-validation NRMSE of 8.1% and an R2 of 0.84 was obtained. The critical parameters influencing the disintegration of the directly compressed ODTs were ascertained using the SHAP method to explain ML model predictions. A reusable, open-source tool, the ODT calculator, is now available at Heroku platform.

1 October 2016 in Computer Methods and Programs in Biomedicine
Verified
Journal Article
Closed access
Jakub SzlękJakub Szlęk
Jakub Szlęk
Adam PacławskiAdam Pacławski
Adam Pacławski
RLRaymond Lau
Raymond Lau
RJRenata Jachowicz
Renata Jachowicz
pezhman kazemipezhman kazemi
pezhman kazemi
Aleksander MendykAleksander Mendyk
Aleksander Mendyk

16 October 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
NŁNatalia Łapińska
Natalia Łapińska
Adam PacławskiAdam Pacławski
Adam Pacławski
Jakub SzlękJakub Szlęk
Jakub Szlęk
Aleksander MendykAleksander Mendyk
Aleksander Mendyk
Introduction of a new drug to the market is a challenging and resource-consuming process. Predictive models developed with the use of artificial intelligence could be the solution to the growing need for an efficient tool which brings practical and knowledge benefits, but requires a large amount of high-quality data. The aim of our project was to develop quantitative structure–activity relationship (QSAR) model predicting serotonergic activity toward the 5-HT1A receptor on the basis of a created database. The dataset was obtained using ZINC and ChEMBL databases. It contained 9440 unique compounds, yielding the largest available database of 5-HT1A ligands with specified pKi value to date. Furthermore, the predictive model was developed using automated machine learning (AutoML) methods. According to the 10-fold cross-validation (10-CV) testing procedure, the root-mean-squared error (RMSE) was 0.5437, and the coefficient of determination (R2) was 0.74. Moreover, the Shapley Additive Explanations method (SHAP) was applied to assess a more in-depth understanding of the influence of variables on the model’s predictions. According to to the problem definition, the developed model can efficiently predict the affinity value for new molecules toward the 5-HT1A receptor on the basis of their structure encoded in the form of molecular descriptors. Usage of this model in screening processes can significantly improve the process of discovery of new drugs in the field of mental diseases and anticancer therapy.